Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 70

1.

Receipt of Palivizumab before Birth Hospitalization Discharge among Preterm Infants in the United States.

La Gamma EF, Kumar VR, Wadhawan R, Ye S, Sifakis F, Ycas J, Ambrose CS.

Am J Perinatol. 2015 Apr 15. [Epub ahead of print]

PMID:
25877742
2.

The Medicaid Cost of Palivizumab.

Ambrose CS, McLaurin KK.

J Pediatric Infect Dis Soc. 2015 Mar;4(1):83-84. No abstract available.

PMID:
25844167
3.

Standard methods based on last menstrual period dates misclassify and overestimate US preterm births.

Ambrose CS, Caspard H, Rizzo C, Stepka EC, Keenan G.

J Perinatol. 2015 Jun;35(6):411-4. doi: 10.1038/jp.2015.25. Epub 2015 Apr 2.

PMID:
25836319
4.

Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis.

Simões EA, Ambrose CS, Wu X, Anderson EJ.

Pediatr Infect Dis J. 2015 Mar;34(3):331. doi: 10.1097/INF.0000000000000566. No abstract available.

PMID:
25742086
5.

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.

Hum Vaccin Immunother. 2014;10(10):2789-94. doi: 10.4161/hv.29635.

PMID:
25483663
6.

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.

Ambrose CS, Chen X, Kumar VR.

Hum Vaccin Immunother. 2014;10(10):2785-8. doi: 10.4161/hv.32082. Epub 2014 Nov 21.

PMID:
25483483
7.

Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United States.

Ambrose CS.

Pediatrics. 2014 Dec;134(6):e1781. doi: 10.1542/peds.2014-2901A. No abstract available.

PMID:
25452648
8.

Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity.

Ambrose CS, Wu X, Caspard H, Belshe RB.

Vaccine. 2014 Sep 29;32(43):5546-8. doi: 10.1016/j.vaccine.2014.07.097. Epub 2014 Aug 12.

9.

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments.

Makari D, Staat MA, Henrickson KJ, Wu X, Ambrose CS.

Clin Pediatr (Phila). 2015 Jun;54(6):594-7. doi: 10.1177/0009922814546040. Epub 2014 Aug 6. No abstract available.

PMID:
25104728
10.

Seasonal influenza vaccination trends from 2007-2011 in privately insured children and adults in the United States.

Antonova E, Ambrose CS, Kern D, Block SL, Caspard H, Tunceli O.

Vaccine. 2014 Nov 12;32(48):6563-8. doi: 10.1016/j.vaccine.2014.07.009. Epub 2014 Jul 18.

11.

Editorial.

Ambrose CS, Bhattacharya J, Fox CB, McIntosh ED, Stern PL.

Ther Adv Vaccines. 2013 May;1(1):3-5. doi: 10.1177/2051013613486264. No abstract available.

12.

Methods to estimate gestational age can significantly affect study results.

Ambrose CS, Rizzo C, Caspard H.

JAMA Pediatr. 2014 Apr;168(4):388. doi: 10.1001/jamapediatrics.2013.5175. No abstract available.

PMID:
24710585
13.

Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.

McLaurin K, Ambrose CS.

Pediatrics. 2014 Apr;133(4):e1101. doi: 10.1542/peds.2014-0077A. No abstract available.

14.

Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, Sifakis F, Groothuis JR.

Pediatr Infect Dis J. 2014 Jun;33(6):576-82. doi: 10.1097/INF.0000000000000219.

15.

Factors associated with in-office influenza vaccination by U.S. pediatric providers.

Lin CJ, Nowalk MP, Toback SL, Ambrose CS.

BMC Pediatr. 2013 Nov 6;13:180. doi: 10.1186/1471-2431-13-180.

16.

The healthcare and societal burden associated with influenza in vaccinated and unvaccinated European and Israeli children.

Ambrose CS, Antonova EN.

Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):569-75. doi: 10.1007/s10096-013-1986-6. Epub 2013 Oct 4.

17.
18.

A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age.

Toback SL, Ambrose CS, Eaton A, Hansen J, Aukes L, Lewis N, Wu X, Baxter R.

Vaccine. 2013 Apr 3;31(14):1812-8. doi: 10.1016/j.vaccine.2013.01.055. Epub 2013 Feb 6.

19.

Improved timing of availability and administration of influenza vaccine through the US Vaccines for Children Program from 2007 to 2011.

Ambrose CS, Toback SL.

Clin Pediatr (Phila). 2013 Mar;52(3):224-30. doi: 10.1177/0009922812470868. Epub 2013 Jan 8.

PMID:
23299840
20.

Effectiveness of intranasal live attenuated influenza vaccine against all-cause acute otitis media in children.

Heikkinen T, Block SL, Toback SL, Wu X, Ambrose CS.

Pediatr Infect Dis J. 2013 Jun;32(6):669-74. doi: 10.1097/INF.0b013e3182840fe7.

PMID:
23271441
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk